← Back to Search

Other

ALTB-268 for Healthy Volunteers

Phase 1
Waitlist Available
Led By Daniel Dickerson, MD
Research Sponsored by AltruBio Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to day 120 of the study
Awards & highlights

Study Summary

This trial will test a drug's safety, how it works in the body, and how it's absorbed and used in healthy people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to day 120 of the study
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to day 120 of the study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of ALTB-268 Treatment-Emergent Adverse Events
Secondary outcome measures
Pharmacokinetics of ALTB-268 AUC (PK) of sc administered ALTB-268 in healthy volunteers.
Pharmacokinetics of ALTB-268 CL/F
Pharmacokinetics of ALTB-268 Cmax
+3 more
Other outcome measures
Exploratory Immunophenotyping Lymphocyte subsets
Pharmacodynamics - change in target engagement biomarkers
Pharmacodynamics of ALTB-268 Receptor Occupancy

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ALTB-268Experimental Treatment1 Intervention
Subcutaneous dose in healthy volunteers
Group II: PlaceboPlacebo Group1 Intervention
Subcutaneous dose in healthy volunteers
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTB-268
2023
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

ICON plcIndustry Sponsor
79 Previous Clinical Trials
23,068 Total Patients Enrolled
AltruBio Inc.Lead Sponsor
3 Previous Clinical Trials
76 Total Patients Enrolled
Daniel Dickerson, MDPrincipal InvestigatorICON plc
2 Previous Clinical Trials
170 Total Patients Enrolled

Media Library

ALTB-268 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05723692 — Phase 1
Healthy Subjects Research Study Groups: ALTB-268, Placebo
Healthy Subjects Clinical Trial 2023: ALTB-268 Highlights & Side Effects. Trial Name: NCT05723692 — Phase 1
ALTB-268 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05723692 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially enroll in this clinical investigation?

"Eligible participants must be in good health and between the ages of 18-55. For this study, 64 people are needed to complete it."

Answered by AI

Are elderly citizens being considered for this experimental treatment?

"This trial requires that participants are aged between 18 to 55 years. For minors, there are 51 clinical trials available and for seniors over 65, 360 studies have been created."

Answered by AI

Is this research endeavor actively enlisting participants?

"According to the details provided on clinicaltrials.gov, this trial is actively seeking participants. The study was first uploaded onto the database on January 17th 2023 and its most recent update happened on February 9th of the same year."

Answered by AI

What implications could ALTB-268 have on human health?

"Data concerning the safety of ALTB-268 is still limited, hence why it received a score of 1. This reflects that this medical trial currently in Phase 1 and lacks extensive evidence on efficacy or safety."

Answered by AI

How many people is the maximum capacity for this investigation?

"Indeed, the information posted on clinicaltrials.gov makes it evident that this medical experiment is currently seeking participants. It was initially announced on January 17th 2023 and most recently updated February 9th of the same year. 64 patients are required from a single location for enrollment."

Answered by AI

Who else is applying?

What state do they live in?
Kansas
What site did they apply to?
ICON Early Development Services
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
~26 spots leftby Mar 2025